DE69621026D1 - Zyklische gmp-spezifische phosphodiesteraseinhibitoren - Google Patents

Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Info

Publication number
DE69621026D1
DE69621026D1 DE69621026T DE69621026T DE69621026D1 DE 69621026 D1 DE69621026 D1 DE 69621026D1 DE 69621026 T DE69621026 T DE 69621026T DE 69621026 T DE69621026 T DE 69621026T DE 69621026 D1 DE69621026 D1 DE 69621026D1
Authority
DE
Germany
Prior art keywords
phosphodiesteras
inhibitors
specific
cyclic gmp
gmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69621026T
Other languages
English (en)
Other versions
DE69621026T2 (de
Inventor
Claude-Marie Daugan
Francoise Gellibert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of DE69621026D1 publication Critical patent/DE69621026D1/de
Publication of DE69621026T2 publication Critical patent/DE69621026T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69621026T 1995-07-14 1996-07-11 Zyklische gmp-spezifische phosphodiesteraseinhibitoren Expired - Fee Related DE69621026T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514465.5A GB9514465D0 (en) 1995-07-14 1995-07-14 Chemical compounds
PCT/EP1996/003025 WO1997003985A1 (en) 1995-07-14 1996-07-11 Cyclic gmp-specific phosphodiesterase inhibitors

Publications (2)

Publication Number Publication Date
DE69621026D1 true DE69621026D1 (de) 2002-06-06
DE69621026T2 DE69621026T2 (de) 2002-08-22

Family

ID=10777696

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69621026T Expired - Fee Related DE69621026T2 (de) 1995-07-14 1996-07-11 Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Country Status (24)

Country Link
US (1) US5981527A (de)
EP (1) EP0846118B1 (de)
JP (1) JP4150818B2 (de)
CN (1) CN1069318C (de)
AR (1) AR003455A1 (de)
AT (1) ATE216997T1 (de)
AU (1) AU702324B2 (de)
BR (1) BR9609780A (de)
CA (1) CA2226761A1 (de)
CO (1) CO4700455A1 (de)
CZ (1) CZ3298A3 (de)
DE (1) DE69621026T2 (de)
ES (1) ES2176471T3 (de)
GB (1) GB9514465D0 (de)
HR (1) HRP960321B1 (de)
HU (1) HUP9900006A3 (de)
IL (1) IL122923A0 (de)
MX (1) MX9800411A (de)
NO (1) NO980154L (de)
PL (1) PL324527A1 (de)
SK (1) SK3898A3 (de)
WO (1) WO1997003985A1 (de)
YU (1) YU42296A (de)
ZA (1) ZA965934B (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
CA2294480C (en) 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
WO2000066114A1 (en) * 1999-04-30 2000-11-09 Lilly Icos Llc Treatment of female arousal disorder
IL135817A0 (en) * 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
ES2310166T3 (es) * 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
US20040152106A1 (en) * 1999-10-07 2004-08-05 Robertson Harold A. Gene necessary for striatal function, uses thereof, and compounds for modulating same
WO2001024781A2 (en) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same
AP2002002455A0 (en) 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
IL139457A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20050020547A1 (en) * 1999-11-08 2005-01-27 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
CA2407031A1 (en) 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
AU5714601A (en) * 2000-04-19 2001-10-30 Univ Johns Hopkins Methods for prevention and treatment of gastrointestinal disorders
JP2004501920A (ja) * 2000-06-23 2004-01-22 リリー　アイコス　リミテッド　ライアビリティ　カンパニー 環状ｇｍｐ特異的ホスホジエステラーゼ阻害剤
MXPA03000887A (es) 2000-08-02 2004-04-05 Lilly Icos Llc Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU8444401A (en) * 2000-09-06 2002-03-22 Tanabe Seiyaku Co Preparations for oral administration
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE297926T1 (de) 2000-10-02 2005-07-15 Lilly Icos Llc Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
EP1335917B1 (de) 2000-10-02 2005-08-24 Lilly Icos LLC Kondensierte pyridoindolderivate
JP4107421B2 (ja) * 2000-11-06 2008-06-25 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅ５阻害剤としてのインドール誘導体
US6960587B2 (en) 2000-11-08 2005-11-01 Lilly Icos Llc Condensed pyrazindione derivatives as PDE inhibitors
KR100750554B1 (ko) * 2001-02-15 2007-08-20 다나베 세이야꾸 가부시키가이샤 구강 내 속붕괴성 정제
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
JP4216709B2 (ja) * 2001-06-05 2009-01-28 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅ５阻害剤としてのテトラ環状化合物
CA2445189C (en) 2001-06-21 2009-02-17 Lilly Icos Llc Carboline derivatives as pdev inhibitors
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
CA2469075C (en) * 2001-12-20 2011-09-13 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as prostaglandin modulators
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
ES2318175T3 (es) * 2002-07-31 2009-05-01 Lilly Icos Llc Reaccion pictet-splenger modificada y productos preparados a partir de la misma.
EP3342420A1 (de) 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung gastrointestinaler erkrankungen
EP1804582A4 (de) * 2004-10-28 2009-12-09 Reddys Lab Ltd Dr Polymorphe formen von tadalafil
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP2218442A1 (de) 2005-11-09 2010-08-18 CombinatoRx, Inc. Verfahren, Zusammensetzungen und Kits zur Behandlung von ophthalmologischen Erkrankungen
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2903619B1 (de) 2012-10-05 2019-06-05 Robert I. Henkin Phosphodiesterasehemmer zur behandlung von geschmacks- und geruchsstörungen
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
EP3082428A4 (de) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5-inhibitorpulverformulierungen und zugehörige verfahren
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
EP3728266A1 (de) 2017-12-20 2020-10-28 Novartis AG Kondensierte tricyclische pyrazolo-dihydropyrazinyl-pyridonverbindungen als viruzide
MX2020008906A (es) * 2018-02-28 2021-02-26 Ferro Therapeutics Inc Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GR79603B (de) * 1982-07-24 1984-10-31 Pfizer
IT1217190B (it) * 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
EP0357122A3 (de) * 1988-08-29 1991-10-23 Duphar International Research B.V Verwendung von Beta-Carbolinen und deren bio-isosterischen Benzofuran- und Benzothiophenanalogen zur Herstellung eines Arzneimittels mit cytostatischer Wirkung
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
ATE113839T1 (de) * 1990-05-31 1994-11-15 Pfizer Arzneimittel gegen impotenz.
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds

Also Published As

Publication number Publication date
NO980154L (no) 1998-03-10
JP4150818B2 (ja) 2008-09-17
SK3898A3 (en) 1998-11-04
CN1195349A (zh) 1998-10-07
AU702324B2 (en) 1999-02-18
HRP960321B1 (en) 2003-06-30
HUP9900006A3 (en) 1999-11-29
HRP960321A2 (en) 1998-08-31
EP0846118A1 (de) 1998-06-10
JPH11509535A (ja) 1999-08-24
CA2226761A1 (en) 1997-02-06
CZ3298A3 (cs) 1998-06-17
MX9800411A (es) 1998-04-30
NO980154D0 (no) 1998-01-13
PL324527A1 (en) 1998-06-08
CO4700455A1 (es) 1998-12-29
CN1069318C (zh) 2001-08-08
AU6419296A (en) 1997-02-18
HUP9900006A2 (hu) 1999-04-28
ATE216997T1 (de) 2002-05-15
WO1997003985A1 (en) 1997-02-06
AR003455A1 (es) 1998-08-05
GB9514465D0 (en) 1995-09-13
ES2176471T3 (es) 2002-12-01
ZA965934B (en) 1997-02-03
IL122923A0 (en) 1998-08-16
BR9609780A (pt) 1999-03-09
US5981527A (en) 1999-11-09
DE69621026T2 (de) 2002-08-22
EP0846118B1 (de) 2002-05-02
YU42296A (sh) 1998-12-23

Similar Documents

Publication Publication Date Title
DE69621026D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE189461T1 (de) Cyclische adhäsionsinhibitoren
NO962381L (no) Spiss-beskytter-innretning
FI963597A0 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
PT858464E (pt) Inibidores de trombina
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
FI951018A0 (fi) Hoeghastighetsdataoeverfoering i mobiltelesystem
DK0904285T3 (da) Cykliske adhæsionsinhibitorer
PT863916E (pt) Tripeptidos de polifluoroalquil triptofano inibidores de trombina
BR9610514A (pt) Inibidores cicloantihelmínticos
KR970703937A (ko) 금속단백질 분해효소 억제제(Metallproteinase inhibitors)
ITBA950021A0 (it) Bobbycar i°
BR9503278A (pt) Dispositivos absorventes bucais
FIU950168U0 (fi) Flyttbar kaota
FI2190U1 (fi) Stoedkonstruktion foer sprutroer i en pappersmaskin/kartongmaskin
FI1803U1 (fi) Anordning i saollskopa
FI1872U1 (fi) I dryckesbackar anvaendbart reklammaterial
FI1900U1 (fi) Spejningsbraeda foer katter i hoeghus
FI2204U1 (fi) Lyftmekanism foer en saekerhetskant i en saeng
FI2050U1 (fi) Rullstol foer fastmontering i fordonsgolv
FI952490A0 (fi) Roerningsapparat foer i synnerhet kallroekning i hemhushaoll
FI955358A0 (fi) Aotkomstfoerfarande foer tvaovaegskommunikation i kabeltelevisionssystem
FI956200A0 (fi) Avvisarlistarrangemang i hisskorg
FI952415A0 (fi) Faerrkotrollsystem foer vaetskemaengden i en behaollare

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee